Mammalian STE20-like Kinase 1 Inhibits Synoviocytes Activation in Rheumatoid Arthritis Through Mitochondrial Dysfunction Mediated by SIRT3/mTOR Axis

Overview

Journal Inflamm Res

Specialties Allergy & Immunology
Pathology

Date 2024 Jan 24

PMID 38265688

Authors

Min Tan

Jing Mao

Jianxiong Zheng

Yu Meng

Jun Li

Jiayao Hao

Haili Shen

Affiliations

Soon will be listed here.

Abstract

Background: Mammalian STE20-like kinase 1 (MST1) is involved in the occurrence of cancer and autoimmune diseases by regulating cell proliferation, differentiation, apoptosis and other functions. However, its role and downstream targets in rheumatoid arthritis (RA) remain unclear.

Methods: The model of RA fibroblast-like synoviocytes (RA-FLSs) overexpressing MST1 was constructed by lentiviral transfection in vitro and analyzed the effects of MST1 on apoptosis, migration, invasion, and inflammation of RA-FLSs. The effect of MST1 on joint synovial membrane inflammation and bone destruction was observed in vivo by establishing a rat model of arthritis with complete Freund's adjuvant.

Results: MST1 is down-regulated in RA-FLSs, and up-regulation of MST1 inhibits the survival, migration, invasion and inflammation of RA-FLSs. Mechanistically, MST1 inhibits SIRT3/mTOR-signaling pathway, inducing decreased mitochondrial autophagy and increased mitochondrial fission, resulting in mitochondrial morphological abnormalities and dysfunction, and ultimately increased apoptosis. We have observed that activation of MST1 alleviates synovial inflammation and bone erosion in vivo.

Conclusions: MST1 reduces the survival, migration, invasion and inflammation of FLSs by inhibiting the SIRT3/mTOR axis to reduce mitochondrial autophagy and promote mitochondrial division, thereby achieving the potential role of relieving rheumatoid arthritis.

References

McInnes I, Schett G . The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011; 365(23):2205-19. DOI: 10.1056/NEJMra1004965. View

Tsaltskan V, Firestein G . Targeting fibroblast-like synoviocytes in rheumatoid arthritis. Curr Opin Pharmacol. 2022; 67:102304. PMC: 9942784. DOI: 10.1016/j.coph.2022.102304. View

Nygaard G, Firestein G . Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol. 2020; 16(6):316-333. PMC: 7987137. DOI: 10.1038/s41584-020-0413-5. View

Cui L, Weiyao J, Chenghong S, Limei L, Xinghua Z, Bo Y . Rheumatoid arthritis and mitochondrial homeostasis: The crossroads of metabolism and immunity. Front Med (Lausanne). 2022; 9:1017650. PMC: 9542797. DOI: 10.3389/fmed.2022.1017650. View

Becker Y, Duvvuri B, Fortin P, Lood C, Boilard E . The role of mitochondria in rheumatic diseases. Nat Rev Rheumatol. 2022; 18(11):621-640. DOI: 10.1038/s41584-022-00834-z. View

Clayton S, MacDonald L, Kurowska-Stolarska M, Clark A . Mitochondria as Key Players in the Pathogenesis and Treatment of Rheumatoid Arthritis. Front Immunol. 2021; 12:673916. PMC: 8118696. DOI: 10.3389/fimmu.2021.673916. View

Kim E, Kwon J, Lee S, Lee E, Kim D, Moon S . IL-17-mediated mitochondrial dysfunction impairs apoptosis in rheumatoid arthritis synovial fibroblasts through activation of autophagy. Cell Death Dis. 2017; 8(1):e2565. PMC: 5386390. DOI: 10.1038/cddis.2016.490. View

Ni H, Williams J, Ding W . Mitochondrial dynamics and mitochondrial quality control. Redox Biol. 2014; 4:6-13. PMC: 4309858. DOI: 10.1016/j.redox.2014.11.006. View

Burtscher M, Burtscher J . MFN2: Shaping mitochondria and cardiac adaptations to hypoxia. Acta Physiol (Oxf). 2023; 239(2):e14026. DOI: 10.1111/apha.14026. View

10.

Rios L, Pokhrel S, Li S, Heo G, Haileselassie B, Mochly-Rosen D . Targeting an allosteric site in dynamin-related protein 1 to inhibit Fis1-mediated mitochondrial dysfunction. Nat Commun. 2023; 14(1):4356. PMC: 10356917. DOI: 10.1038/s41467-023-40043-0. View

11.

Zhang J, Xiang H, Liu J, Chen Y, He R, Liu B . Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target. Theranostics. 2020; 10(18):8315-8342. PMC: 7381741. DOI: 10.7150/thno.45922. View

12.

Hussain M, Haris M, Khan M, Mahjabeen I . Role of mitochondrial sirtuins in rheumatoid arthritis. Biochem Biophys Res Commun. 2021; 584:60-65. DOI: 10.1016/j.bbrc.2021.11.016. View

13.

Radu M, Chernoff J . The DeMSTification of mammalian Ste20 kinases. Curr Biol. 2009; 19(10):R421-5. DOI: 10.1016/j.cub.2009.04.022. View

14.

Wang Y, Jia A, Cao Y, Hu X, Wang Y, Yang Q . Hippo Kinases MST1/2 Regulate Immune Cell Functions in Cancer, Infection, and Autoimmune Diseases. Crit Rev Eukaryot Gene Expr. 2021; 30(5):427-442. DOI: 10.1615/CritRevEukaryotGeneExpr.2020035775. View

15.

Li Q, Qi F, Meng X, Zhu C, Gao Y . Mst1 regulates colorectal cancer stress response via inhibiting Bnip3-related mitophagy by activation of JNK/p53 pathway. Cell Biol Toxicol. 2017; 34(4):263-277. DOI: 10.1007/s10565-017-9417-6. View

16.

Wang X, Song Q . Mst1 regulates post-infarction cardiac injury through the JNK-Drp1-mitochondrial fission pathway. Cell Mol Biol Lett. 2018; 23:21. PMC: 5941482. DOI: 10.1186/s11658-018-0085-1. View

17.

Li H, Feng J, Zhang Y, Feng J, Wang Q, Zhao S . Mst1 deletion attenuates renal ischaemia-reperfusion injury: The role of microtubule cytoskeleton dynamics, mitochondrial fission and the GSK3β-p53 signalling pathway. Redox Biol. 2018; 20:261-274. PMC: 6205415. DOI: 10.1016/j.redox.2018.10.012. View

18.

She G, Du J, Wu W, Pu T, Zhang Y, Bai R . Hippo pathway activation mediates chemotherapy-induced anti-cancer effect and cardiomyopathy through causing mitochondrial damage and dysfunction. Theranostics. 2023; 13(2):560-577. PMC: 9830444. DOI: 10.7150/thno.79227. View

19.

Reszka A, Masarachia P, Rodan G . Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem. 1999; 274(49):34967-73. DOI: 10.1074/jbc.274.49.34967. View

20.

Zvaifler N . Relevance of the stroma and epithelial-mesenchymal transition (EMT) for the rheumatic diseases. Arthritis Res Ther. 2006; 8(3):210. PMC: 1526619. DOI: 10.1186/ar1963. View